Multiple myeloma - The Lancet
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Daratumumab Forms Backbone of Triplet Regimens in Transplant Ineligible Multiple Myeloma
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Updated Perspectives on the Management of Multiple Myeloma in Older Pa | CIA
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Cancers | Free Full-Text | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond | HTML
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, E | CMAR
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Multiple myeloma - The Lancet
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple My
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma | HTML
Federal Practitioner - 0918 Current Trends in MM - Current Trends in Multiple Myeloma
Short overview on the current standard of treatment in newly diagnosed multiple myeloma | SpringerLink
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
